Payment overview · 2025
General Payments
$3,446.89
155 reported records · 24 companies
Healthcare provider profile · identity verified
Todd B Dunaway, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · TULSA, OK · NPI 1982624268
Verified facts
What the public records show
CMS Open Payments records show Todd B Dunaway, MD received $3,446.89 in general payments during 2025 across 155 reported records.
TG Therapeutics, Inc. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Evrysdi as an associated drug or biological on 569 records involving 252 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Evrysdi by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $480.32 | 13.9% | 15 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $466.22 | 13.5% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $387.93 | 11.2% | 27 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $338.13 | 9.8% | 22 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $233.57 | 6.8% | 11 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $233.00 | 6.8% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $213.87 | 6.2% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$171.09 | 5.0% | 8 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $150.41 | 4.4% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $131.32 | 3.8% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $126.12 | 3.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $105.78 | 3.1% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $72.70 | 2.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.77 | 1.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.66 | 1.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.64 | 1.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.13 | 1.0% | 2 | 2025 |
| ITF Therapeutics LLC | Unresolved — no canonical attribution shown | $32.89 | 0.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.82 | 0.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.03 | 0.7% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.77 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.75 | 0.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.69 | 0.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.28 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,343.93 | 153 |
| Education | $102.96 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $480.32 | 15 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $338.13 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $262.65 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $262.65 | 20 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $194.25 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $193.73 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $152.82 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $150.41 | 9 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $131.32 | 5 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $126.12 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $122.34 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $109.11 | 6 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $97.83 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $95.91 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $80.18 | 3 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $72.70 | 4 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $69.67 | 4 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $67.99 | 3 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $67.99 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.77 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.77 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $46.70 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 88 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
92 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Evrysdi open payments reported associated product |
CMS Open Payments — General Payments 569 supporting records · 252 recipient NPIs · example record 1211488410 |
Evrysdi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 376 | 84 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 264 | 56 |
| Donepezil Hcl | Donepezil Hcl | 183 | 55 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 151 | 41 |
| Memantine Hcl | Memantine Hcl | 148 | 32 |
| Baclofen | Baclofen | 134 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 110 | 23 |
| Gabapentin | Gabapentin | 103 | 25 |
| Lamotrigine | Lamotrigine | 98 | 26 |
| Trazodone Hcl | Trazodone Hcl | 95 | 26 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 92 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 88 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 15 |
| Levetiracetam | Levetiracetam | 71 | 21 |
| Clonazepam | Clonazepam | 65 | 14 |
| Amantadine | Amantadine Hcl | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 12 |
| Riluzole | Riluzole | 53 | suppressed |
| Pregabalin | Pregabalin | 50 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 45 | 12 |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 39 | suppressed |
| Dalfampridine Er | Dalfampridine | 39 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 39 | suppressed |
| Prednisone | Prednisone | 39 | 17 |
| Primidone | Primidone | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 35 | suppressed |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | 12 |
| Diazepam | Diazepam | 31 | 11 |
| Lacosamide | Lacosamide | 31 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Copaxone | Glatiramer Acetate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 23 | suppressed |
| Kesimpta Pen | Ofatumumab | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 12 |
| Armodafinil | Armodafinil | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 16 | suppressed |
| Evrysdi | Risdiplam | 15 | suppressed |
| Glatopa | Glatiramer Acetate | 15 | suppressed |
| Rytary | Carbidopa/Levodopa | 15 | suppressed |
| Solu-Cortef | Hydrocortisone Sodium Succ/Pf | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Sodium Oxybate | Sodium Oxybate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,446.89 · 155 records | TG Therapeutics, Inc. | AUSTEDO XR, BOTOX, BRIUMVI, Briviact, EPIDIOLEX, Enspryng, FABRAZYME, FIRDAPSE, Fintepla, Gamunex-C, HYQVIA, Hizentra, KESIMPTA, Leqembi, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PONVORY, QALSODY, QULIPTA, Qelbree, Rystiggo, SKYCLARYS, SPINRAZA, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYVGART, VYVGART HYTRULO, WAINUA, ZAVZPRET, ZEPOSIA, Zilbrysq | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CSL Behring?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error